Renal Autologous Cell Therapy in Type 2 Diabetes with Late Stage 4 Diabetes-Related Chronic Kidney Disease: Trial Design and Early Analysis
Blood Purification · 2023 · 52 (2) · 114-121
DOI: 10.1159/000527582 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood Purification, online erschienen am 04.01.2023. Verfasst von Joseph Stavas und 6 weiteren Autor:innen. Beteiligte Einrichtung: ProKidney, Raleigh, North Carolina, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetic Nephropathies, Kidney Failure, Chronic. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction
Cell-based therapies potentially delay the trajectory toward end-stage kidney disease (ESKD) in late stage 4 diabetic chronic kidney disease (DKD). We describe the trial design, baseline patient characteristics, and early results of an IRB-approved phase II multicenter clinical trial, utilizing Renal Autologous Cell Therapy (REACT) in adults with pre-ESKD due to type 2 DKD. The trial objectives were safety and tolerability of REACT by assessment of the procedure, product administration, and renal-specific adverse events in addition to evaluate the impact on renal function following injection.
Methods
Ten adults with an eGFR of 14–20 mL/min/1.73 m2 were enrolled in a single-arm open-label trial. Following a percutaneous kidney biopsy, an ex vivo expansion of selected renal cells that form the REACT was injected into the cortex of the biopsied kidney with CT image guidance. Each participant received two doses of the REACT product at 6-month intervals. A 6-month observation pre-trial was required to establish patients’ “own” baseline and rate of DKD progression.
Results
Five men and 5 women underwent 19 REACT injections (1 participant received only one injection). Their baseline characteristics were as follows: 3 Hispanic/Latino, 7 non-Hispanic, 7 white; mean (SD) age: 58.9 years (5.22), BMI 35.8 (8.2), eGFR (sCR) 15.5 (2.72), eGFR (sCR + Cys-C) 17.7 (3.67) mL/min/1.73 m2, sCr 3.6 mg/mL (0.73), Cys-C 2.6 mg/mL (0.52), and log random UACR 7.9 mg/g (1.01). The pre- and post-injection eGFR slope was −6.5 mL/min/1.73 m2 and −3.9 mL/min/1.73 m2. No cell-related adverse events occurred, and two procedure-related hematomas required observation without transfusion or angiographic interventions. Dialysis was delayed a mean of 16 months (range 6–28 months). At 15 months, 2 patients (20%) have eGFR slope stability and have not commenced renal replacement therapy.
Conclusion
Trials that include patients with an eGFR of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- ProKidney, Raleigh, North Carolina, USA.
- Department of Medicine, Banner University of Arizona School of Medicine, Tucson, Arizona, USA.
- Department of Medicine, Icahn School of Medicine at Mt. Sinai, New York, New York, USA.
- Boise Kidney and Hypertension, Boise, Idaho, USA.
- Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Zitieren
APA
Stavas, J., Thajudeen, B., Coca, S., Silva, A., Butler, E., Detwiler, R., & Burgner, A. (2023). Renal Autologous Cell Therapy in Type 2 Diabetes with Late Stage 4 Diabetes-Related Chronic Kidney Disease: Trial Design and Early Analysis. Blood Purification, 52(2), 114-121. https://doi.org/10.1159/000527582
Vancouver
Stavas J, Thajudeen B, Coca S, Silva A, Butler E, Detwiler R, et al. Renal Autologous Cell Therapy in Type 2 Diabetes with Late Stage 4 Diabetes-Related Chronic Kidney Disease: Trial Design and Early Analysis. Blood Purification. 2023;52(2):114-121. doi:10.1159/000527582
BibTeX
@article{Stavas2023,
author = {Stavas, Joseph and Thajudeen, Bijin and Coca, Steven and Silva, Arnold and Butler, Emily and Detwiler, Randal and Burgner, Anna},
title = {Renal Autologous Cell Therapy in Type 2 Diabetes with Late Stage 4 Diabetes-Related Chronic Kidney Disease: Trial Design and Early Analysis},
journal = {Blood Purification},
year = {2023},
volume = {52},
number = {2},
pages = {114--121},
doi = {10.1159/000527582}
}
EUVIMED